Integrating chemohormonal therapy and surgery in known or suspected lymph node metastatic prostate cancer.

ABSTRACT:

Background

Prostate cancer persisting in the primary site after systemic therapy may contribute to emergence of resistance and progression. We previously demonstrated molecular characteristics of lethal cancer in the prostatectomy specimens of patients presenting with lymph node metastasis after chemohormonal treatment. Here we report the post-treatment outcomes of these patients and assess whether a link exists between surgery and treatment-free/cancer-free survival.

Methods

Patients with either clinically detected lymph node metastasis or primaries at high risk for nodal dissemination were treated with androgen ablation and docetaxel. Those responding with PSA concentration <1 ng ml(-1) were recommended surgery 1 year from enrollment. ADT was withheld postoperatively. The

SUBMITTER: Zurita AJ 

PROVIDER: S-EPMC4821010 | biostudies-literature | 2015 Sep

REPOSITORIES: biostudies-literature